Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,981.00    1.50 (0.08%)
Bid:
1,977.00
Ask:
1,978.00
Spread: 1.00 (0.051%)
Market Cap: £79.37b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Director/PDMR Shareholding

11 Jan 2022 16:28

RNS Number : 1194Y
GlaxoSmithKline PLC
11 January 2022
 

GlaxoSmithKline plc (the 'Company')

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr H Barron

b)

Position/status

Chief Scientific Officer and President, R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W1053

b)

Nature of the transaction

Acquisition of notional ADSs within Dr Barron's GSK Executive Supplemental Savings Plan account.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

$43.8500

1,037.605

 

 

 

 

 

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

 

e)

Date of the transaction

2022-01-07

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr H Barron

b)

Position/status

Chief Scientific Officer and President, R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W1053

b)

Nature of the transaction

Acquisition of ADSs within Dr Barron's GSK 401(k) Plan account.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

$43.8500

186

 

 

 

 

 

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

 

e)

Date of the transaction

2022-01-07

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHQFLFFLFLLBBQ
Date   Source Headline
13th May 20257:00 amRNSTransaction in Own Shares
12th May 20253:31 pmRNSBlock listing Interim Review
12th May 20257:00 amRNSTransaction in Own Shares
9th May 20257:00 amRNSTransaction in Own Shares
8th May 20255:15 pmRNSDirector/PDMR Shareholding
8th May 20253:30 pmRNSDirector/PDMR Shareholding
8th May 202511:15 amRNSLinerixibat GLISTEN pIII trial data at EASL
8th May 20257:00 amRNSTransaction in Own Shares
7th May 20256:22 pmRNSResult of AGM
7th May 20257:00 amRNSTransaction in Own Shares
6th May 20257:00 amRNSTransaction in Own Shares
2nd May 20257:00 amRNSTransaction in Own Shares
1st May 20253:30 pmRNSDirector/PDMR Shareholding
1st May 20253:00 pmRNSTotal Voting Rights
1st May 20257:00 amRNSNucala MATINEE data in COPD published in NEJM
1st May 20257:00 amRNSTransaction in Own Shares
30th Apr 20257:05 amRNSTransaction in Own Shares
30th Apr 20257:00 amRNS1st Quarter Results
29th Apr 20257:00 amRNSTransaction in Own Shares
28th Apr 20257:00 amRNSTransaction in Own Shares
25th Apr 20257:00 amRNSTransaction in Own Shares
24th Apr 20257:00 amRNSTransaction in Own Shares
23rd Apr 20257:00 amRNSTransaction in Own Shares
22nd Apr 20257:00 amRNSTransaction in Own Shares
17th Apr 20254:13 pmRNSBlenrep licensed by UK MHRA
17th Apr 20253:30 pmRNSDirector/PDMR Shareholding
17th Apr 20257:10 amRNSArexvy now ACIP recommended for 50-59 at risk
17th Apr 20257:05 amRNSGSK 5-in-1 meningitis vaccine recommended in US
17th Apr 20257:00 amRNSTransaction in Own Shares
16th Apr 20257:00 amRNSTransaction in Own Shares
15th Apr 20253:30 pmRNSDirector/PDMR Shareholding
15th Apr 20257:00 amRNSTransaction in Own Shares
14th Apr 20257:00 amRNSTransaction in Own Shares
11th Apr 20253:30 pmRNSDirector/PDMR Shareholding
11th Apr 20257:00 amRNSTransaction in Own Shares
10th Apr 20257:00 amRNSTransaction in Own Shares
9th Apr 20257:00 amRNSTransaction in Own Shares
8th Apr 20257:00 amRNSTransaction in Own Shares
7th Apr 20257:00 amRNSTransaction in Own Shares
4th Apr 20257:00 amRNSTransaction in Own Shares
3rd Apr 20257:00 amRNSTransaction in Own Shares
2nd Apr 20257:00 amRNSTransaction in Own Shares
1st Apr 20253:30 pmRNSTotal Voting Rights
1st Apr 20257:00 amRNSTransaction in Own Shares
31st Mar 20257:00 amRNSTransaction in Own Shares
28th Mar 20253:30 pmRNSDirector/PDMR Shareholding
28th Mar 20257:00 amRNSTransaction in Own Shares
27th Mar 20257:00 amRNSTransaction in Own Shares
26th Mar 20257:00 amRNSTransaction in Own Shares
25th Mar 20254:34 pmRNSGSK uUTI treatment approved by US FDA

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.